New drug duo aims to shrink tough lung tumors

NCT ID NCT07154290

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 35 times

Summary

This study tests two experimental drugs, ubamatamab and REGN7075, in 300 people with advanced non-small cell lung cancer that has spread. The goal is to see if the combination can shrink tumors and control the disease. A third drug, sarilumab, may be used to manage immune-related side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Treatment Centers of America, Phoenix
RECRUITING

Goodyear, Arizona, 85338, United States
Franciscan Health
RECRUITING

Munster, Indiana, 46321, United States
The City of Hope Orange County Lennar Foundation Cancer Center
RECRUITING

Irvine, California, 92618, United States
University of Maryland Greenebaum Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States
University of Tennessee Medical Center
RECRUITING

Knoxville, Tennessee, 37920, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER